NCT04619680View on ClinicalTrials.gov

The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19

PHASE4CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

February 1, 2024

Study Completion Date

March 2, 2024

Conditions
Pulmonary FibrosisInterstitial Lung DiseaseRespiratory Disease
Interventions
DRUG

Nintedanib

150 mg PO twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).

DRUG

Placebo

placebo 150 mg equivalent twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).

Trial Locations (7)

10003

Mount Sinai Beth Israel, New York

10029

Icahn School of Medicine at Mount Sinai, New York

21287

The Johns Hopkins Hospital, Baltimore

30322

Emory Healthcare Network, Atlanta

75246

Baylor University Medical Center Dallas, Dallas

77030

Baylor College of Medicine, Houston

84108

University of Utah, Salt Lake City

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT04619680 - The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19 | Biotech Hunter | Biotech Hunter